Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
作者信息
Bahji Anees, Vazquez Gustavo H, Zarate Carlos A
机构信息
Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
Department of Psychiatry, Queen's University, Kingston, Ontario, Canada.
出版信息
J Affect Disord. 2021 Mar 1;282:258-260. doi: 10.1016/j.jad.2020.12.069. Epub 2020 Dec 24.
Abstract
摘要
相似文献
1
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?对艾司氯胺酮与氯胺酮疗效比较的荟萃分析评论的回应：本末倒置？
J Affect Disord. 2021 Mar 1;282:258-260. doi: 10.1016/j.jad.2020.12.069. Epub 2020 Dec 24.
2
Esketamine for treatment resistant depression: a trick of smoke and mirrors?用于治疗抵抗性抑郁症的 Esketamine：烟雾与镜子的把戏？
Epidemiol Psychiatr Sci. 2019 Dec 16;29:e79. doi: 10.1017/S2045796019000751.
3
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.总结氯胺酮和艾司氯胺酮治疗难治性抑郁症的证据：现有证据和实施情况的国际专家意见。
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
4
Esketamine as a treatment for paediatric depression: questions of safety and efficacy.艾氯胺酮作为儿童抑郁症的治疗方法：安全性和有效性问题。
Lancet Psychiatry. 2020 Oct;7(10):827-829. doi: 10.1016/S2215-0366(19)30521-8. Epub 2020 Jan 14.
5
Esketamine for treatment resistant depression.艾氯胺酮用于治疗难治性抑郁症。
Expert Rev Neurother. 2019 Oct;19(10):899-911. doi: 10.1080/14737175.2019.1640604. Epub 2019 Jul 16.
6
Esketamine (Spravato) for Treatment-Resistant Depression.艾氯胺酮（斯普拉维托）用于治疗抵抗性抑郁症。
Am Fam Physician. 2020 Mar 15;101(6):339-340.
7
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.灵活剂量依他佐辛鼻喷雾剂联合新起始口服抗抑郁药治疗难治性抑郁症的疗效和安全性：一项随机、双盲、活性对照研究。
Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21.
8
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg.氯胺酮和艾司氯胺酮治疗难治性抑郁症：对雷乌斯、马茨和沙茨伯格的回应。
Am J Psychiatry. 2021 Dec;178(12):1130-1132. doi: 10.1176/appi.ajp.2021.21060653r.
9
A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.氯胺酮和艾司氯胺酮治疗难治性抑郁症中自杀观念疗效的系统评价和荟萃分析。
Eur J Clin Pharmacol. 2024 Feb;80(2):287-296. doi: 10.1007/s00228-023-03605-1. Epub 2023 Dec 20.
10
Esketamine clinical trials: reply to Maju .依他佐辛临床试验：回复马朱。
Epidemiol Psychiatr Sci. 2020 Apr 29;29:e122. doi: 10.1017/S204579602000027X.
引用本文的文献
1
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence.氯胺酮治疗创伤后应激障碍的潜力：临床证据综述
Ther Adv Psychopharmacol. 2023 Mar 6;13:20451253231154125. doi: 10.1177/20451253231154125. eCollection 2023.
2
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.消旋卡前列素与依他硝唑治疗抑郁症的疗效和安全性：系统评价和荟萃分析。
Expert Opin Drug Saf. 2022 Jun;21(6):853-866. doi: 10.1080/14740338.2022.2047928. Epub 2022 Mar 9.
本文引用的文献
1
Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis.辅助治疗急性双相抑郁的疗效和耐受性比较：系统评价和网络荟萃分析。
Can J Psychiatry. 2021 Mar;66(3):274-288. doi: 10.1177/0706743720970857. Epub 2020 Nov 11.
2
Ketamine: A tale of two enantiomers.氯胺酮：对映异构体的两面性。
J Psychopharmacol. 2021 Feb;35(2):109-123. doi: 10.1177/0269881120959644. Epub 2020 Nov 6.
3
Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression.健康受试者和治疗抵抗性抑郁症患者中艾司氯胺酮鼻喷雾剂及其代谢物去甲氯胺酮的群体药代动力学。
Clin Pharmacokinet. 2021 Apr;60(4):501-516. doi: 10.1007/s40262-020-00953-4. Epub 2020 Oct 31.
4
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.消旋卡前列素与依他佐辛治疗抑郁症的疗效比较：系统评价和荟萃分析。
J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23.
5
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.静脉注射、鼻内和口服氯胺酮治疗心境障碍的效果：一项荟萃分析。
J Affect Disord. 2020 Nov 1;276:576-584. doi: 10.1016/j.jad.2020.06.050. Epub 2020 Jul 21.
6
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).依他佐辛鼻腔喷雾剂治疗伴有自杀意念的重度抑郁症患者快速缓解抑郁症状的 3 期、双盲、随机研究（ASPIRE II）结果。
Int J Neuropsychopharmacol. 2021 Jan 20;24(1):22-31. doi: 10.1093/ijnp/pyaa068.
7
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review.艾氯胺酮：治疗难治性抑郁症的新希望？一篇叙述性综述。
Ther Adv Drug Saf. 2020 Jul 23;11:2042098620937899. doi: 10.1177/2042098620937899. eCollection 2020.
8
Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.艾氯胺酮鼻喷雾剂在美国治疗抵抗性抑郁症患者中的成本效益
Psychiatr Serv. 2020 Oct 1;71(10):988-997. doi: 10.1176/appi.ps.201900625. Epub 2020 Jul 7.
9
Clinical overview of NMDA-R antagonists and clinical practice.N-甲基-D-天冬氨酸受体拮抗剂的临床概述与临床实践
Adv Pharmacol. 2020;89:103-129. doi: 10.1016/bs.apha.2020.04.004. Epub 2020 Jun 1.
10
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.依他佐辛鼻喷雾剂附加治疗与附加第二代抗精神病药物治疗对难治性重度抑郁症的治疗反应。
Int J Neuropsychopharmacol. 2020 Jul 29;23(7):440-445. doi: 10.1093/ijnp/pyaa034.
Zotero 插件